Skip to main
MNKD
MNKD logo

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corporation demonstrates a positive outlook due to its potential advancements with Furoscix, particularly if the auto-injector receives approval, which could significantly enhance the company's revenue stream. The possibility of label expansion for the Tyvaso DPI version is viewed as a fundamental driver for MannKind’s stock, especially amid ongoing developments in treatments for conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Arterial Hypertension (PAH). Additionally, the successful deal with SCPH is crucial as it reinforces market confidence in MannKind's capital allocation strategy, complementing anticipated peak sales growth for Furoscix despite its niche market characteristics.

Bears say

MannKind Corporation's stock has experienced a significant decline, attributed to competitive pressures following SQ Innovation's approval of a competing product priced at approximately 50% lower than Furoscix. Additionally, expectations for Afrezza's sales, projected at $127 million by 2030, may prove overly optimistic, considering the inherent risks and uncertainties surrounding the pediatric market opportunity and pipeline projects MNKD-101 and MNKD-201, with low probability of success. Overall, the impact of market reactions to pricing uncertainties and competitive products, alongside cautious sales forecasts, raises concerns regarding MannKind's future financial stability and growth potential.

MannKind (MNKD) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 5 analysts, MannKind (MNKD) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.